Secobarbitalum Natricum Veterinary Grade API is the sodium salt of 5-allyl-5-(1-methylbutyl)barbituric acid, CAS 309-43-3, molecular formula C12H17N2NaO3. The material is released as a white to almost white hygroscopic crystalline powder in two particle-size models: a non-micronized model with D50 75–150 µm as measured by laser diffraction under ISO 13320:2020, and a micronized model with D50 15–50 µm. The micronized model is specified for low-dose tablets, capsules, dry granules, and medicated premixes where the active content in the final blend is ≤ 1.0% w/w; the non-micronized model is retained for high-dose dry powders and for preparation of concentrated aqueous solutions. The model designation appears on the certificate of analysis as SEC-Na-VET-M for micronized and SEC-Na-VET-N for non-micronized grade. Both models are released under the same assay and impurity specification because the particle-size designation does not alter the compendial identity or purity requirements.

Incoming bulk containers are tested for loss on drying by USP <731> with a limit of ≤ 3.0% w/w. The powder is stored in double polyethylene-lined fibre drums at 15–25°C and protected from humidity. If storage relative humidity exceeds 60% RH, the material is pre-dried at 50–60°C under vacuum until loss on drying ≤ 1.0% w/w before any dry granulation or direct compression operation. This pre-drying step is mandatory because residual moisture above 3.0% w/w increases contact surface area between the active and excipients, causing capping and reduced tablet hardness during compaction.

For direct compression, the micronized model is first passed through an 80-mesh (177 µm) screen and blended in a V-blender or bin blender at 10–15 rpm for 15–20 min. The fill volume is maintained at ≤ 60% of total blender capacity. Blend uniformity is verified using USP <905> Uniformity of Dosage Units: a blend containing 0.5% w/w API is accepted only when the acceptance value is ≤ 15.0 for 10 units, and the relative standard deviation of blend samples taken from 10 locations is ≤ 3.0%. Because secobarbitalum natricum has a typical bulk density of 0.35–0.50 g/mL, the addition of 0.5–1.0% w/w colloidal silicon dioxide is usually required to reduce the compressibility index below 20% when tested according to USP <1174>.

What Defines a Veterinary-Grade API Grade Cut for Secobarbitalum Natricum?

The veterinary-grade API cut is defined less by active identity than by the intersection of compendial release limits, residual solvent burden, and microbial quality that determines suitability for parenteral and oral finished products. Secobarbitalum Natricum intended for veterinary tablets, injections, capsules, powders, granules, premixes, and solutions is released against the following matrix. Every cell is verified on a lot-by-lot basis through an audit trail maintained under 21 CFR 211.160.

Assay is performed by reversed-phase HPLC with an octadecylsilyl column; the mobile phase contains acetonitrile and phosphate buffer adjusted to pH 4.0, with UV detection at 220 nm. Under these conditions secobarbitalum natricum elutes as a single peak resolved from the free acid and from the principal hydrolytic degradation product. Lots above the upper assay limit are rejected because the sodium salt may contain residual free acid; lots below the lower assay limit are rejected for insufficient potency. The residual solvent limit of 0.5% w/w follows ICH Q3C Class 3 Option 1, which is suitable for an API that can enter parenteral formulations.

Particle-size boundaries, press settings, and the risk of content uniformity drift

For low-dose dry blends, the micronized model of secobarbitalum natricum is passed through an 80-mesh (177 µm) screen immediately before blending; the non-micronized model is unsuitable below 1.0% w/w active because segregation during bin discharge increases the content uniformity acceptance value above 15.0 under USP <905>. In a rotary tablet press operating at 25–40 rpm with 8 mm flat-faced tooling and a compression force of 5–12 kN, the micronized API produces tablets of hardness 5–8 kp. Friability remains ≤ 1.0% w/w after 100 rotations in a drum friabilator under USP <1216> only when moisture is ≤ 1.0% w/w and the blend contains a suitable dry binder.

For capsule filling, the API is pre-dried to loss on drying ≤ 1.0% w/w and compacted by slugging or roller compaction. Roller-compacted granules are milled to D50 180–250 µm and filled on a semi-automatic capsule machine; fill weight variation across 20 consecutively filled capsules is limited to ≤ 3.0% RSD. Because the molecule is heat-labile in the presence of alkaline moisture, dry granulation is preferred over aqueous wet granulation.

When aqueous wet granulation cannot be avoided, water is excluded as the granulation solvent. Anhydrous ethanol or isopropanol with 5% w/w povidone K30 is used, and the granulate is dried at 40°C under vacuum. Water at alkaline pH catalyses ring-opening hydrolysis of the barbiturate nucleus; a pH excursion above 10.0 for longer than 4 h at 25°C is controlled by adjustment to pH 8.0–9.0 before addition of heat-labile excipients.

For medicated premixes and powders intended for feed administration, the micronized model is diluted stepwise with lactose monohydrate or corn starch in a double-cone blender at 12 rpm for 20 min per dilution step. The premix intermediate is tested by taking 10 samples from different blender locations and demonstrating active content 95.0%–105.0% of label claim. Inclusion rates below 0.1% w/w in final feed require a geometric dilution series to avoid carry-over and segregation.

When the sodium salt enters aqueous compounding: hydrolysis, pH, and terminal sterilisation

Secobarbitalum natricum is freely soluble in carbon-dioxide-free water at 20±2°C; typical stock solutions at 5–10% w/v are prepared with stirring at 200–400 rpm in stainless steel vessels. The solution pH is measured by USP <791>; concentrated solutions usually fall in the alkaline range because the barbiturate anion is the conjugate base of a weak acid. The pH is buffered or adjusted into the validated range before terminal sterilisation. The API solution is light-sensitive; holding under 20–25°C and diffuse light for more than 24 h without light shielding increases visible colour intensity.

The aqueous degradation rate is lowest near pH 8.0–9.0. At pH above 10.5, hydrolysis of the barbiturate ring is accelerated; at pH below 3.0 the free acid precipitates and chemical hydrolysis pathways change. Terminal sterilisation at 121°C for 15 min is acceptable only for buffered formulations that show assay loss ≤ 2.0% and total related substances ≤ 1.5% after a worst-case thermal cycle. When terminal moist-heat sterilisation cannot be justified, sterile filtration through a 0.22 µm polyvinylidene difluoride filter is used, but the preceding bulk solution must still meet the endotoxin limit set by Ph. Eur. 2.6.14.

For parenteral veterinary products, the sterile API is dissolved in Water for Injection in a Grade B/ISO 7 cleanroom and filtered under aseptic conditions. Sodium chloride is used to adjust tonicity to 300±30 mOsm/kg as measured by freezing point osmometry under USP <785>. The filter is integrity tested by bubble point or diffusion flow with the filter manufacturer’s specified minimum bubble point; for a typical water-wetted polyvinylidene difluoride membrane this is ≥ 45 psi. Nitrogen overlay is applied during filling to reduce oxidative degradation of the allyl substituent.

Comparative release traits among barbiturate sodium salt APIs

Secobarbitalum natricum differs from pentobarbital sodium and phenobarbital sodium in the C5 substituents of the barbiturate nucleus. Secobarbital carries an allyl group and a 1-methylbutyl group; pentobarbital sodium carries an ethyl group and a 1-methylbutyl group. The allyl substitution increases lipid solubility and shortens central nervous system depression relative to phenobarbital sodium, which is classified as a long-acting barbiturate. This solubility difference directly influences formulation selection.

The sodium salt of secobarbital is preferred for injectable or rapidly dissolving oral preparations, whereas the free acid form, CAS 76-73-3, is poorly water-soluble and reserved for suspension or specialty oral dosage forms. In dry blends, direct contact with strong acids or oxidising agents is avoided because the allyl group is susceptible to oxidation. The sodium salt should not be combined with acidic buffer salts that lower pH below 7.0 in aqueous solution, as this may form the less-soluble free acid and reduce filter throughput during sterile filtration.

Published data for production-scale veterinary secobarbitalum natricum configurations is limited, particularly for feed premixes; release testing is therefore based on the individual product marketing authorisation rather than a harmonized global standard. Secobarbital sodium remains controlled under national veterinary controlled substance schedules, and its import, export, and warehousing require tamper-evident storage and bonded inventory records.